Silymarin and hepatocellular carcinoma: A systematic, comprehensive, and critical review

Anti-Cancer Drugs

Volumn 26, Issue 5, 2014, Pages 475-486

  Mastron, Jeanetta K ^a   Siveen, Kodappully S ^c,d   Sethi, Gautam ^c   Bishayee, Anupam ^b,e  

^a American University of Health Sciences   (United States)

^b CALIFORNIA NORTHSTATE UNIVERSITY   (United States)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d HAMAD MEDICAL CORPORATION   (Qatar)

^e Larkin Health Science Institute   (United States)

Author keywords

chemoprevention; hepatocellular carcinoma; milk thistle; silibinin; silymarin; treatment

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; ANTIOXIDANT; SILYMARIN;

CHEMISTRY; HUMAN; LIVER NEOPLASMS; SILYBUM MARIANUM; TUMOR CELL LINE;

ANTI-INFLAMMATORY AGENTS; ANTICARCINOGENIC AGENTS; ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; CELL LINE, TUMOR; HUMANS; LIVER NEOPLASMS; MILK THISTLE; SILYMARIN;

EID: 84939942887     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0000000000000211     Document Type: Review

References (111)

1. Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 2010; 19:1893-1907.
2. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009; 27:1485-1491.
3. World Cancer Research Fund International (WCRFI). Cancer statistics, data on specific cancers: Liver cancer. London: World Cancer Research Fund International; 2012.
4. GLOBOCAN. Liver cancer estimated incidence, mortality and prevalence worldwide in 2012: At a glance. France: World Health Organization (WHO), International Agency for Research on Cancer (IARC); 2012.
5. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61:69-90.
6. American Cancer Society. Cancer facts and figures 2014. Atlanta, GA: American Cancer Society; 2014.
7. Venook AP, Papandreou C, Furuse J, De Guevara LL. The incidence and epidemiology of hepatocellular carcinoma: A global and regional perspective. Oncologist 2010; 15 Suppl 4:5-13.
8. Chen JG, Zhang SW. Liver cancer epidemic in China: Past, present and future. Semin Cancer Biol 2011; 21:59-69.
9. Wang YC, Wei LJ, Liu JT, Li SX, Wang QS. Comparison of Cancer Incidence between China and the USA. Cancer Biol Med 2012; 9:128-132.
10. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014; 64:9-29.
11. Maki A, Kono H, Gupta M, Asakawa M, Suzuki T, Matsuda M, et al. Predictive power of biomarkers of oxidative stress and inflammation in patients with hepatitis C virus-associated hepatocellular carcinoma. Ann Surg Oncol 2007; 14:1182-1190.
12. Marra M, Sordelli IM, Lombardi A, Lamberti M, Tarantino L, Giudice A, et al. Molecular targets and oxidative stress biomarkers in hepatocellular carcinoma: An overview. J Transl Med 2011; 9:171.
13. Liu Y,Wu F. Global burden of aflatoxin-induced hepatocellular carcinoma: A risk assessment. Environ Health Perspect 2010; 118:818-824.
14. Tajiri K, Shimizu Y. Liver physiology and liver diseases in the elderly. World J Gastroenterol 2013; 19:8459-8467.
15. World Gastroenterology Organisation Global Guidelines (WGOGG). Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Milwaukee:World Gastroenterology Organisation Global Guidelines; 2012. pp. 1-2.
16. Kodama K, Tokushige K, Hashimoto E, Taniai M, Shiratori K. Hepatic and extrahepatic malignancies in cirrhosis caused by nonalcoholic steatohepatitis and alcoholic liver disease. Alcohol Clin Exp Res 2013; 37 Suppl 1:E247-E252.
17. Bosch FX, Ribes J, Díaz M, Cléries R. Primary liver cancer: Worldwide incidence and trends. Gastroenterology 2004; 127 (5 Suppl 1):S5-S16.
18. Bialecki ES, Di Bisceglie AM. Diagnosis of hepatocellular carcinoma. HPB (Oxford) 2005; 7:26-34.
19. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42:1208-1236.
20. Davis GL, Dempster J, Meler JD, Orr DW, Walberg MW, Brown B, et al. Hepatocellular carcinoma: Management of an increasingly common problem. Proc (Bayl Univ Med Cent) 2008; 21:266-280.
21. Tsuzuki T, Sugioka A, Ueda M, Iida S, Kanai T, Yoshii H, Nakayasu K. Hepatic resection for hepatocellular carcinoma. Surgery 1990; 107:511-520.
22. Peabody JW, Taguiwalo MM, Robalino DA, Frenk J. Improving the quality of care in developing countries disease control priorities in developing countries, 2nd edn. Washington: World Bank; 2006.
23. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J-F, et al. SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359:378-390.
24. Keating GM, Santoro A. Sorafenib: A review of its use in advanced hepatocellular carcinoma. Drugs 2009; 69:223-240.
25. Brandi G, De Rosa F, Calzà L, Girolamo SD, Tufoni M, Ricci CS, et al. Can the tyrosine kinase inhibitors trigger metabolic encephalopathy in cirrhotic patients? Liver Int 2013; 33:488-493.
26. American Cancer Society. Cancer facts and figures 2013. Atlanta, GA: American Cancer Society; 2013.
27. Brandi G, De Rosa F, Agostini V, di Girolamo S, Andreone P, Bolondi L, et al. Metronomic capecitabine in advanced hepatocellular carcinoma patients: A phase II study. Oncologist 2013; 18:1256-1257.
28. Brose MS, Frenette CT, Keefe SM, Stein SM. Management of sorafenibrelated adverse events: A clinician's perspective. Semin Oncol 2014; 41: S1-S16.
29. AL-Tamimi FA, Hegazi AEM. A case of castor bean poisoning. Sultan Qaboos Univ Med J 2008; 8:83-87.
30. Aggarwal BB, Shishodia S. Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol 2006; 71:1397-1421.
31. Cragg GM, Grothaus PG, Newman DJ. Impact of natural products on developing new anti-cancer agents. Chem Rev 2009; 109:3012-3043.
32. Geldenhuys WJ, Bishayee A, Darvesh AS, Carroll RT. Natural products of dietary origin as lead compounds in virtual screening and drug design. Curr Pharm Biotechnol 2012; 13:117-124.
33. Aune D, De Stefani E, Ronco A, Boffetta P, Deneo-Pellegrini H, Acosta G, Mendilaharsu M. Legume intake and the risk of cancer: A multisite casecontrol study in Uruguay. Cancer Causes Control 2009; 20:1605-1615.
34. Ros E. Health benefits of nut consumption. Nutrients 2010; 2:652-682.
35. Dinicola S, Cucina A, Pasqualato A, Proietti S, D'Anselmi F, Pasqua G, et al. Apoptosis-inducing factor and caspase-dependent apoptotic pathways triggered by different grape seed extracts on human colon cancer cell line Caco-2. Br J Nutr 2010; 104:824-832.
36. Huang WY, Cai YZ, Zhang Y. Natural phenolic compounds from medicinal herbs and dietary plants: Potential use for cancer prevention. Nutr Cancer 2010; 62:1-20.
37. Kaefer CM, Milner JA. The role of herbs and spices in cancer prevention. J Nutr Biochem 2008; 19:347-361.
38. Moiseeva EP, Manson MM. Dietary chemopreventive phytochemicals: Too little or too much? Cancer Prev Res (Phila) 2009; 2:611-616.
39. Lee KW, Bode AM, Dong Z. Molecular targets of phytochemicals for cancer prevention. Nat Rev Cancer 2011; 11:211-218.
40. Naithani R, Huma LC, Moriarty RM, McCormick DL, Mehta RG. Comprehensive review of cancer chemopreventive agents evaluated in experimental carcinogenesis models and clinical trials. Curr Med Chem 2008 15 1044-1071
41. Nishino H. Phytochemicals in hepatocellular cancer prevention. Nutr Cancer 2009; 61:789-791.
42. Morgan TR. Chemoprevention of hepatocellular carcinoma in chronic hepatitis C. Recent Results Cancer Res 2011; 188:85-99.
43. Bishayee A, Thoppil RJ, Waghray A, Kruse JA, Novotny NA, Darvesh AS. Dietary phytochemicals in the chemoprevention and treatment of hepatocellular carcinoma: In vivo evidence, molecular targets, and clinical relevance. Curr Cancer Drug Targets 2012; 12:1191-1232.
44. Shimizu M, Kubota M, Tanaka T, Moriwaki H. Nutraceutical approach for preventing obesity-related colorectal and liver carcinogenesis. Int J Mol Sci 2012; 13:579-595.
45. Singh S, Singh PP, Roberts LR, Sanchez W. Chemopreventive strategies in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2014; 11:45-54.
46. Thoppil RJ, Bishayee A. Terpenoids as potential chemopreventive and therapeutic agents in liver cancer. World J Hepatol 2011; 3:228-249.
47. Luo H, Tang L, Tang M, Billam M, Huang T, Yu J, et al. Phase IIa chemoprevention trial of green tea polyphenols in high-risk individuals of liver cancer: Modulation of urinary excretion of green tea polyphenols and 8-hydroxydeoxyguanosine. Carcinogenesis 2006; 27:262-268.
48. Darvesh AS, Bishayee A. Chemopreventive and therapeutic potential of tea polyphenols in hepatocellular cancer. Nutr Cancer 2013; 65:329-344.
49. Darvesh AS, Aggarwal BB, Bishayee A. Curcumin and liver cancer: A review. Curr Pharm Biotechnol 2012; 13:218-228.
50. Bishayee A, Politis T, Darvesh AS. Resveratrol in the chemoprevention and treatment of hepatocellular carcinoma. Cancer Treat Rev 2010; 36:43-53.
51. Glauert HP, Calfee-Mason K, Stemm DN, Tharappel JC, Spear BT. Dietary antioxidants in the prevention of hepatocarcinogenesis: A review. Mol Nutr Food Res 2010; 54:875-896.
52. Hu Y, Wang S, Wu X, Zhang J, Chen R, Chen M, Wang Y. Chinese herbal medicine-derived compounds for cancer therapy: A focus on hepatocellular carcinoma. J Ethnopharmacol 2013; 149:601-612.
53. Manach C, Scalbert A, Morand C, Rémésy C, Jiménez L. Polyphenols: Food sources and bioavailability. Am J Clin Nutr 2004; 79:727-747.
54. Pérez-Jiménez J, Neveu V, Vos F, Scalbert A. Identification of the 100 richest dietary sources of polyphenols: An application of the Phenol-Explorer database. Eur J Clin Nutr 2010; 64 Suppl 3:112-120.
55. Wahle KW, Brown I, Rotondo D, Heys SD. Plant phenolics in the prevention and treatment of cancer. Adv Exp Med Biol 2010; 698:36-51.
56. Stagos D, Amoutzias GD, Matakos A, Spyrou A, Tsatsakis AM, Kouretas D. Chemoprevention of liver cancer by plant polyphenols. Food Chem Toxicol 2012; 50:2155-2170.
57. Cheung CW, Gibbons N, Johnson DW, Nicol DL. Silibinin-A promising new treatment for cancer. Anticancer Agents Med Chem 2010; 10:186-195.
58. Vaid M, Katiyar SK. Molecular mechanisms of inhibition of photocarcinogenesis by silymarin, a phytochemical from milk thistle (Silybum marianum L. Gaertn.) (Review). Int J Oncol 2010; 36:1053-1060.
59. Deep G, Agarwal R. Antimetastatic efficacy of silibinin: Molecular mechanisms and therapeutic potential against cancer. Cancer Metastasis Rev 2010; 29:447-463.
60. Raina K, Agarwal R. Promise and potential of silibinin in colorectal cancer management: What patterns can be seen? Future Oncol 2013; 9:759-761.
61. Mateen S, Raina K, Agarwal R. Chemopreventive and anti-cancer efficacy of silibinin against growth and progression of lung cancer. Nutr Cancer 2013; 65 Suppl 1:3-11.
62. Ting H, Deep G, Agarwal R. Molecular mechanisms of silibinin-mediated cancer chemoprevention with major emphasis on prostate cancer. AAPS J 2013; 15:707-716.
63. Deep G, Agarwal R. Targeting tumor microenvironment with silibinin: Promise and potential for a translational cancer chemopreventive strategy. Curr Cancer Drug Targets 2013; 13:486-499.
64. Karimi G, Vahabzadeh M, Lari P, Rashedinia M, Moshiri M. "Silymarin", a promising pharmacological agent for treatment of diseases. Iran J Basic Med Sci 2011; 14:308-317.
65. American Cancer Society. Milk thistle Complementary and alternative medicine: Herbs, vitamins and minerals. Atlanta: American Cancer Society; 2009.
66. Post-White J, Ladas EJ, Kelly KM. Advances in the use of milk thistle (Silybum marianum). Integr Cancer Ther 2007; 6:104-109.
67. Davis-Searles PR, Nakanishi Y, Kim NC, Graf TN, Oberlies NH, Wani MC, et al. Milk thistle and prostate cancer: Differential effects of pure flavonolignans from Silybum marianum on antiproliferative end points in human prostate carcinoma cells. Cancer Res 2005; 65:4448-4457.
68. Mengs U, Pohl RT, Mitchell T. Legalon® SIL: The antidote of choice in patients with acute hepatotoxicity from amatoxin poisoning. Curr Pharm Biotechnol 2012; 13:1964-1970.
69. Rainone F. Milk thistle. Am Fam Physician 2005; 72:1285-1288.
70. National Center for Complementary and Alternative Medicine (NCCAM), NIH National Institute of Health. Herbs at a glance: Milk thistle. Bethesda: National Center for Complementary and Alternative Medicine (NCCAM), NIH National Institutes of Health; 2012.
71. Ramakrishnan G, Lo Muzio L, Elinos-Báez CM, Jagan S, Augustine TA, Kamaraj S, et al. Silymarin inhibited proliferation and induced apoptosis in hepatic cancer cells. Cell Prolif 2009; 42:229-240.
72. Chen CH, Huang TS, Wong CH, Hong CL, Tsai YH, Liang CC, et al. Synergistic anti-cancer effect of baicalein and silymarin on human hepatoma HepG2 Cells. Food Chem Toxicol 2009; 47:638-644.
73. Varghese L, Agarwal C, Tyagi A, Singh RP, Agarwal R. Silibinin efficacy against human hepatocellular carcinoma. Clin Cancer Res 2005; 11:8441-8448.
74. Pook SH, Toh CK, Mahendran R. Combination of thiol antioxidant Silibinin with Brostallicin is associated with increase in the anti-apoptotic protein Bcl-2 and decrease in caspase 3 activity. Cancer Lett 2006; 238:146-152.
75. Lah JJ, Cui W, Hu KQ. Effects and mechanisms of silibinin on human hepatoma cell lines. World J Gastroenterol 2007; 13:5299-5305.
76. Momeny M, Khorramizadeh MR, Ghaffari SH, Yousefi M, Yekaninejad MS, Esmaeili R, et al. Effects of silibinin on cell growth and invasive properties of a human hepatocellular carcinoma cell line, HepG-2, through inhibition of extracellular signal-regulated kinase 1/2 phosphorylation. Eur J Pharmacol 2008; 591:13-20.
77. García-Maceira P, Mateo J. Silibinin inhibits hypoxia-inducible factor-1alpha and mTOR/p70S6K/4E-BP1 signalling pathway in human cervical and hepatoma cancer cells: Implications for anticancer therapy. Oncogene 2009; 28:313-324.
78. Angeli JP, Barcelos GR, Serpeloni JM, Barbosa F Jr, Nersesyan A, Mantovani MS. Evaluation of the genotoxic and anti-genotoxic activities of silybin in human hepatoma cells (HepG2). Mutagenesis 2010; 25:223-229.
79. Brandon-Warner E, Sugg JA, Schrum LW, McKillop IH. Silibinin inhibits ethanol metabolism and ethanol-dependent cell proliferation in an in vitro model of hepatocellular carcinoma. Cancer Lett 2010; 291:120-129.
80. Bousserouel S, Bour G, Kauntz H, Gossé F, Marescaux J, Raul F. Silibinin inhibits tumor growth in a murine orthotopic hepatocarcinoma model and activates the TRAIL apoptotic signaling pathway. Anticancer Res 2012; 32:2455-2462.
81. Ghasemi R, Ghaffari SH, Momeny M, Pirouzpanah S, Yousefi M, Malehmir M, et al. Multitargeting and antimetastatic potentials of silibinin in human HepG-2 and PLC/PRF/5 hepatoma cells. Nutr Cancer 2013; 65:590-599.
82. Zhang S, Yang Y, Liang Z, Duan W, Yang J, Yan J, et al. Silybin-mediated inhibition of Notch signaling exerts antitumor activity in human hepatocellular carcinoma cells. PLoS One 2013; 8:e83699.
83. Dvorák Z, Vrzal R, Ulrichová J. Silybin and dehydrosilybin inhibit cytochrome P450 1A1 catalytic activity: A study in human keratinocytes and human hepatoma cells. Cell Biol Toxicol 2006; 22:81-90.
84. Huber A, Thongphasuk P, Erben G, Lehmann WD, Tuma S, Stremmel W, Chamulitrat W. Significantly greater antioxidant anticancer activities of 2,3-dehydrosilybin than silybin. Biochim Biophys Acta 2008; 1780:837-847.
85. Ramakrishnan G, Raghavendran HR, Vinodhkumar R, Devaki T. Suppression of N-nitrosodiethylamine induced hepatocarcinogenesis by silymarin in rats. Chem Biol Interact 2006; 161:104-114.
86. Pradeep K, Mohan CV, Gobianand K, Karthikeyan S. Silymarin modulates the oxidant-antioxidant imbalance during diethylnitrosamine induced oxidative stress in rats. Eur J Pharmacol 2007; 560:110-116.
87. Ramakrishnan G, Augustine TA, Jagan S, Vinodhkumar R, Devaki T. Effect of silymarin on N-nitrosodiethylamine induced hepatocarcinogenesis in rats. Exp Oncol 2007; 29:39-44.
88. Ramakrishnan G, Elinos-Báez CM, Jagan S, Augustine TA, Kamaraj S, Anandakumar P, Devaki T. Silymarin downregulates COX-2 expression and attenuates hyperlipidemia during NDEA-induced rat hepatocellular carcinoma. Mol Cell Biochem 2008; 313:53-61.
89. Ramakrishnan G, Jagan S, Kamaraj S, Anandakumar P, Devaki T. Silymarin attenuated mast cell recruitment thereby decreased the expressions of matrix metalloproteinases-2 and 9 in rat liver carcinogenesis. Invest New Drugs 2009; 27:233-240.
90. Gopalakrishnan R, Sundaram J, Sattu K, Pandi A, Thiruvengadam D. Dietary supplementation of silymarin is associated with decreased cell proliferation increased apoptosis, and activation of detoxification system in hepatocellular carcinoma. Mol Cell Biochem 2013; 377:163-176.
91. El Mesallamy HO, Metwally NS, Soliman MS, Ahmed KA, Abdel Moaty MM. The chemopreventive effect of Ginkgo biloba and Silybum marianum extracts on hepatocarcinogenesis in rats. Cancer Cell Int 2011; 11:38.
92. Imamoto R, Okano JI, Sawada S, Fujise Y, Abe R, Murawaki Y. Null anticarcinogenic effect of silymarin on diethylnitrosamine-induced hepatocarcinogenesis in rats. Exp Ther Med 2014; 7:31-38.
93. Wu YF, Fu SL, Kao CH, Yang CW, Lin CH, Hsu MT, Tsai TF. Chemopreventive effect of silymarin on liver pathology in HBV X protein transgenic mice. Cancer Res 2008; 68:2033-2042.
94. Cui W, Gu F, Hu KQ. Effects and mechanisms of silibinin on human hepatocellular carcinoma xenografts in nude mice. World J Gastroenterol 2009; 15:1943-1950.
95. Brandon-Warner E, Eheim AL, Foureau DM, Walling TL, Schrum LW, McKillop IH. Silibinin (milk thistle) potentiates ethanol-dependent hepatocellular carcinoma progression in male mice. Cancer Lett 2012; 326:88-95.
96. Coussens LM, Raymond WW, Bergers G, Laig-Webster M, Behrendtsen O, Werb Z, et al. Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes Dev 1999; 13:1382-1397.
97. Gao J, Chen Y, Wu KC, Liu J, Zhao YQ, Pan YL, et al. RUNX3 directly interacts with intracellular domain of Notch1 and suppresses Notch signaling in hepatocellular carcinoma cells. Exp Cell Res 2010; 316:149-157.
98. El-Kamary SS, Shardell MD, Abdel-Hamid M, Ismail S, El-Ateek M, Metwally M, et al. A randomized controlled trial to assess the safety and efficacy of silymarin on symptoms, signs and biomarkers of acute hepatitis. Phytomedicine 2009; 16:391-400.
99. Hawke RL, Schrieber SJ, Soule TA, Wen Z, Smith PC, Reddy KR, et al. SyNCH Trial Group. Silymarin ascending multiple oral dosing phase I study in noncirrhotic patients with chronic hepatitis C. J Clin Pharmacol 2010; 50:434-449.
100. Fried MW, Navarro VJ, Afdhal N, Belle SH, Wahed AS, Hawke RL, et al. Silymarin in NASH and C Hepatitis (SyNCH) Study Group. Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy: A randomized controlled trial. JAMA 2012; 308:274-282.
101. Yakoot M, Salem A. Spirulina platensis versus silymarin in the treatment of chronic hepatitis C virus infection. A pilot randomized, comparative clinical trial. BMC Gastroenterol 2012; 12:32.
102. Schrieber SJ, Hawke RL, Wen Z, Smith PC, Reddy KR, Wahed AS, et al. Differences in the disposition of silymarin between patients with nonalcoholic fatty liver disease and chronic hepatitis C. Drug Metab Dispos 2011; 39:2182-2190.
103. Freedman ND, Curto TM, Morishima C, Seeff LB, Goodman ZD, Wright EC, et al. HALT-C Trial Group. Silymarin use and liver disease progression in the Hepatitis C Antiviral Long-Term Treatment against Cirrhosis trial. Aliment Pharmacol Ther 2011; 33:127-137.
104. Guedj J, Dahari H, Pohl RT, Ferenci P, Perelson AS. Understanding silibinin's modes of action against HCV using viral kinetic modeling. J Hepatol 2012; 56:1019-1024.
105. Mariño Z, Crespo G, D'Amato M, Brambilla N, Giacovelli G, Rovati L, et al. Intravenous silibinin monotherapy shows significant antiviral activity in HCVinfected patients in the peri-transplantation period. J Hepatol 2013; 58:415-420.
106. Bárcena R, Moreno A, Rodríguez-Gandía MA, Albillos A, Arocena C, Blesa C, et al. Hospital Ramón y Cajal Liver Transplant Group. Safety and anti-HCV effect of prolonged intravenous silibinin in HCV genotype 1 subjects in the immediate liver transplant period. J Hepatol 2013; 58:421-426.
107. Siegel AB, Narayan R, Rodriguez R, Goyal A, Jacobson JS, Kelly K, et al. A phase I dose-finding study of silybin phosphatidylcholine (milk thistle) in patients with advanced hepatocellular carcinoma. Integr Cancer Ther 2014; 13:46-53.
108. De Kok TM, Van Breda SG, Manson MM. Mechanisms of combined action of different chemopreventive dietary compounds: A review. Eur J Nutr 2008; 47 Suppl 2:51-59.
109. Bode AM, Dong Z. Epigallocatechin 3-gallate and green tea catechins: United they work, divided they fail. Cancer Prev Res (Phila) 2009; 2:514-517.
110. Ulrich-Merzenich G, Zeitler H, Vetter H, Kraft K. Synergy research: Vitamins and secondary plant components in the maintenance of the redoxhomeostasis and in cell signaling. Phytomedicine 2009; 16:2-16.
111. Wang Y, Zhang L, Wang Q, Zhang D. Recent advances in the nanotechnology-based drug delivery of Silybin. J Biomed Nanotechnol 2014; 10:543-558.